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Abstract Traditional medicinal practices play a key role in health care systems in countries with developing economies.
The aim of this survey was to validate the use of traditional medicine within local Nigerian communities. In this review, we
examine the ethnobotanical uses of selected plant species from the Nigerian flora and attempt to correlate the activities of
the isolated bioactive principles with known uses of the plant species in African traditional medicine. Thirty-three (33)
plant species were identified and about 100 out of the 120 compounds identified with these plants matched with the
ethnobotanical uses of the plants.
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1 Introduction
It is estimated that 66–85 % of the world’s population
depends directly on plants as medicines [1–3]. Since the
existence of human civilization, plants and their by-pro-
ducts have been used by a large proportion of the popu-
lation living in rural and urban areas for various purposes
such as medicine, healthcare, food, clothing, shelter, agri-
culture, agrochemicals, pharmaceuticals, narcotics, etc.
The sum total of this is referred to as ethnobotany [4].
Medicinal plants are defined as plants having one or more
organs containing substances that can be used for thera-
peutic purposes or which are precursors for the synthesis of
useful drugs [5]. Thus, medicinal plants represent, for the
local population, a possibility of simple and cheap treat-
ment. In addition, they represent sources of potentially
important new pharmaceutical substances since all parts of
a plant, from roots to seed heads and flowers, are employed
in traditional remedies and can therefore act as sources of
lead compounds [6]. More than 80 % of the world’s pop-
ulations, especially in developing countries, depend on
traditional systems of medicine for the treatment of a
variety of diseases. This observation could be attributed to
two main factors; inaccessibility of modern drugs and the
low purchasing power within the populations living in the
rural areas [7]. Moreover, some of the local remedies work
and so the populations have no need for anything different.
From antiquity, mankind has been developing a tradi-
tional medicinal system, based on the knowledge of
medicinal plants throughout the world [8]. Africans, in
particular, have used medicinal plants and animal-derived
remedies in their struggle for survival and in their quest for
religious experiences. The World Health Organization
(WHO) defines traditional medicine as practices, knowledge
and belief systems which use minerals, plants and animal
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based remedies, spiritual therapies and exercises to prevent,
treat and maintain wellbeing [9]. This knowledge became
enriched over numerous generations due to experimentation
but also through observations of animal behaviour [10].
Most often, knowledge of traditional medicine is only
inherited orally, thereby facing the danger of being lost in
favor of Western medicine (WM). Many Africans believe in
the manifestation of life forces or spirits in every creation,
and that these spirits constitute the heart of all life forms,
natural events or non-living things. This gives herbal med-
icine a vital role in health care delivery systems especially in
remote areas where clinics and hospitals are sparsely located
[8, 11]. Despite the advances in WM, African traditional
medicine (ATM) has gained renewed interest in the health
care services throughout the continent. This could probably
be due to the rapidly increasing awareness of the potential
and curative abilities of alternative medicines, especially
from the use of medicinal plants, as well as the inadequate
access to WM and physicians and the high cost for Western
drugs [12]. The argument for the local African populations
resorting to traditional remedies could also be partly justi-
fied by the fact that natural product inspired molecules
represented about 80 % of drugs that had been put into the
market [1, 13].
Previous ethnobotanical studies of medicinal plants
confirm the rational use of recipes by different people or
groups from different communities [14]. Numerous varie-
ties of medicinal plants growing in Africa are widely used
against many diseases ranging from endemic tropical dis-
eases like malaria [15] and leishmaniasis [16] to complex
illnesses such as asthma [17], psychosis [18], hepatitis [19]
and even cancer [20]. Searching for new lead compounds
to be developed as drugs or as templates for analogue
synthesis and the evaluation of traditional medicine and
herbal medicinal products, are the two basic reasons for the
advancement of work on medicinal plants [21]. The use of
plant preparations can be supported if it is safe and if their
biological activity can be scientifically confirmed. This
calls for quality control and standardization. If the activity
cannot be confirmed, and certainly if there is a risk of
toxicity, the use of herbal medicinal products should be
discouraged [21]. The study of plants used traditionally as
medicines is therefore an interesting discipline because of
the possibility to find new drugs and also because of the
strong adhesion of local populations, for the aforemen-
tioned reasons [11–13, 22, 23]. This has prompted many
research teams to carry out studies on plants used in Africa
by traditional healers against diseases.
The United Nations definition of Western Africa
includes the following 16 countries: Benin, Burkina Faso,
Cape Verde, Ivory Coast, the Gambia, Ghana, Guinea,
Guinea-Bissau, Liberia, Mali, Mauritania, Niger, Nigeria,
Senegal, Sierra Leone and Togo. These countries occupy
an area of over 6,140,000 km2 and the natural environment
in this area consists of subtropical and tropical regions with
semi-arid and humid climates [14]. In these communities,
traditional herbalists operate closer to the people, taking
advantage of the biodiversity of plant species in such areas
to cure various diseases and ailments.
Nigeria is located in West Africa on the Gulf of Guinea
and shares borders with Cameroon (1,690 km) in the East,
Chad (87 km) in the Northeast, Niger (1,497 km) in the
North, Benin (773 km) in the West and the Atlantic Ocean in
the South (Fig. 1) [24]. The country is divided administra-
tively into the Federal Capital Territory (Abuja) and 36 states
[25]. As a result of the large surface area occupied by
Nigeria, the national territory covers different climatic and
ecological zones. Nigeria is rich in biodiversity, with an
array of fauna and flora. These include about 20,000 species
of insects, almost 1,000 species of birds, 247 species of
mammals, 123 species of reptiles, about 1,000 species of fish
and about 7,895 species of plants [26]. Consequently ATM is
a common and acceptable practice in Nigeria as in many
countries in Africa and Asia. Many plants from the Nigerian
flora which provide very useful clues for potential thera-
peutic compounds have been investigated by mostly uni-
versity research groups. Some of the plants investigated are
commonly used in the treatment of several microbial infec-
tions [27], a range of neglected tropical diseases including
malaria [28], trypanosomiasis [29], as well as diabetes [30]
and diverse infections. It is therefore very important to sci-
entifically document the available knowledge for its
exploitation towards the enhancement of human health [31].
Several attempts towards the documenting of ethnobo-
tanical and ethnopharmacological knowledge for medicinal
plants in Nigeria have been carried out. Raphael has pro-
vided a useful work on traditional medicine in Nigeria,
about its current status and the future [1], while Soladoye
et al. [32] provided a list of 143 plant species belonging to
58 families which were found to be useful for the treatment
of haemorrhoids in South Western Nigeria. Idowu et al.
[33] also carried out an ethnobotanical survey around Ogun
State, South Western Nigeria, in which 38 plant species
belonging to 24 families were identified to be used in
herbal anti-malarial recipes, while Ajibesin et al. [34]
identified a total of 114 medicinal plant species repre-
senting 102 genera and 54 families employed in the tra-
ditional medical practice of the people of Akwa Ibom
State, Nigeria. Adetutu et al. [35] carried out a similar
survey of wound-healing plants, while Sonibare and Gbile,
listed plants that are being used in the treatment of asthma
in South Western Nigeria [17]. Gbolade made an inventory
of plants used in the treatment of diabetes in Lagos State
and plants used in treating hypertension in Edo State of
Nigeria [36, 37]. Idu et al. [38] conducted an ethnobotan-
ical survey of plants among the Esan Tribe of Edo State,
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and identified 32 plant species belonging to 31 genera and
23 families which have been used for oral healthcare.
One of the goals of our research centre is to document
and establish knowledge bases for chemical substances,
including those derived from plant use in ATM. Our
previous studies have been focused on Central Africa [13,
39–41], including the pharmacokinetics profiling of natural
products (NPs) derived from plant materials [42–44]. It
has been our aim to extend the study to different regions
and eventually to cover the entire continent of Africa. Due
to the different works carried out by different research
teams on the Nigerian flora, the aim of this survey is to
identify those plants used traditionally for the treatment of
various ailments in Nigeria that show promising lead-like
activity. Our focus has been on the NPs whose measured
biological activities correlate with the use of the plant in
ATM. In this survey, the ethnobotanical uses of the plant
species from Nigeria versus the bioactivities of the derived
NPs are presented by plant family and in alphabetical
order.
2 Alliaceae, Amaryllidaceae, Annonaceae,
Apocynaceae, Asteraceae and Bignoniaceae
The ethnobotanical uses of plants in the above families are
shown in Table 1, along with the biological activities of the
most remarkable isolated NPs. The biological activities
which correlate with the enthnobotanical uses of the plants
have been highlighted in bold. From the Alliaceae family,
ajoene (1) and allicin (2), Fig. 2, were isolated from the
bulb of Allium sativum (commonly known as garlic), a
plant traditionally used in Nigeria for the treatment of
malaria, among diverse uses [45]. Ajeone was active
against Plasmodium berghei in mice [46], thus validating
the ethnobotanical use of the plant, meanwhile allicin was
reported as a P. falciparum cysteine protease inhibitor [47].
It should be mentioned that rodent malaria is a well-known
animal model for testing new compounds and plant
extracts. However, trial in humans is decisive to identify a
‘‘hit’’ as ‘‘a real hit’’; and this is a good way to assess
toxicity and safety. Crinum glaucum is used in the
Fig. 1 Map showing Nigeria and her neighbours [24]
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treatment of cough, asthma, and convulsions in Nigeria
[48, 49], while Crinum jagus is a plant used in traditional
medicine, either singly or in a combination with Chro-
moleana odorata and Emilia prateramisa (both of
Asteraceae family) in the treatment of all forms of con-
vulsion [50]. Compounds 3–8 represent potent alkaloids
isolated from Crinum sp. (Amaryllidaceae), which exhibit
acetylcholinesterase inhibition, the most active alkaloids
Table 1 Summary of ethnobotanical uses versus measured biological activities of isolated secondary metabolites from; Alliaceae, Amaryl-
lidaceae, Annonaceae, Apocynaceae, Asteraceae and Bignoniaceae plant families





Measured activity Author and References
Alliaceae Allium sativum Treatment of malaria, seasoning
food, cleansing of blood,
prevention and fighting of common
cold, boost testosterone levels,
regulation of blood sugar levels
and as an antiseptic
Bulb 1 and 2 Antiplasmodial activity Adebayo et al. [45],
Perez et al. [46],
Coppi et al. [47]
Amaryllidaceae Crinum glaucum Used in the treatment of cough,
asthma, and convulsions. The plant










[48] Houghton et al.
[50]
Crinum jagus Treatment of all forms of









Azikiwe et al. [49],
Houghton et al. [50],
Kim et al. [51]
Annonaceae Enantia
chlorantha
Treatment of malaria, jaundice,
dysentery, hypertension, skin,
gastric and duodenal ulcers,
inflammation, and liver-related




9 and 10 Antiplasmodial and
antiviral activities
Adebayo et al. [45],
Bhadra and Kumar
[52], Bidla et al., [53],
Jia et al. [54]















Adebayo et al., [45],
Ezeamuzie et al. [55],





Treatment of malaria and measles,
cutaneous, subcutaneous parasitic
infection, rheumatic pains,
diarrhea, dysentery as well as
venereal diseases, as an
abortifacient, and in the treatment
of inflammatory and tumor-
related ailments. Also used in the
preparation of soup in the South





Kasim et al. [58],
Kupchan et al. [59],
Liobikas et al. [60],
Gnoatto et al. [61]
Bignoniaceae Spathodea
campanulata
Extracts of bark, leaves and flowers




skin diseases, wounds, fever,
urethral inflammation, liver








Adebayo et al. [45]
Treatment of diseases (ulcers,
dysentery, oedemas, skin
eruptions, scabies, wound healing
and urethral discharge) and
veterinary application have been












Antioxidant activity Elusiyan et al. [62],
Picerno et al. [63]
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isolated being hamayne (7, IC50 = 250 lM) and lycorine
(5, IC50 = 450 lM), while the other alkaloids were com-
paratively inactive, with haemanthamane (6) giving 3 %
inhibition and crinamine (8) giving 4.4 % inhibition at
50 mg mL-1 (174 lM). These results contrast with the
positive control physostigmine which gave IC50 of
0.25 lM. Thus, cholinesterase activity appears to be
associated with the presence of two free hydroxy groups in
this structural type of Amaryllidaceae alkaloids. Crinamine
has also been isolated from the aerial parts of the Asian
subspecies Crinum asiaticum var. japonicum together with
lycorine, norgalanthamine and epinorgalanthamine [51].
The compound showed potent dose dependent inhibition
(IC50 = 2.7 lM) of HIF-1a in a cell-based reporter gene
assay [51]. The other components of the Asian subspecies
(from Korea) showed no significant inhibition of HIF-1a
induced transcriptional activity.
Enantia chlorantha (Annonaceae) is an ornamental tree,
of up to 30 meters in height, with dense foliage and
spreading crown. It’s stem bark is used against fever/
malaria by traditional medicine practitioners in the forest
regions [44], in addition to its use in the treatment of
jaundice, dysentery, hypertension, inflammation, and liver-
related diseases [52]. The isolated compounds palmatine (9)
and jatrorrhizine (10) are known to exhibit anti-malarial
activity [53], while palmatine also has weak in vitro activity
against flavivirus [54]. Seven compounds with anti-malarial
properties; akuammicine (11), akuammine (12), alstonine
(13), picraline (14), picratidine (15) picranitidine (16) and
w-akuammigine (17) have been isolated from the stem bark
and seeds of Picralima nitida (Apocynaceae), a plant used
in the treatment of malaria and in the management of pains
and other ailments [55, 56]. Based on these results, an
enterprising Ghanaian hospital started manufacturing
standardised 250 mg capsules of the powdered P. nitida
seed, and sold around the country where they became
widely accepted as a safe and effective pain relief product.
The extract showed potent and dose-dependent anti-
inflammatory, anti-pyretic and anti-malarial activities.
Given intraperitoneally, this extract inhibited carrageenan-
induced rat paw oedema with IC50 of 102 mg kg
-1, and
with the highest dose tested (300 mg kg-1) producing
72.2 % inhibition. On the LPS-induced pyrexia in rabbits,
50 mg kg-1 of the extract produced a mean percentage
antipyrexia of (38.7 %) compared with (29.0 %) by
200 mg kg-1 of aspirin. In a 4-day in vivo schizontocidal
test in mice infected with P. berghei, up to 300 mg kg-1
daily for 4 days was ineffective in preventing the develop-
ment of parasitaemia or the consequent mortality. However,
marked inhibitory activity was obtained on multi-drug
resistant human P. falciparium parasites cultured in vitro.
The dose causing 50 % inhibition of parasite growth was
1.75 lg mL-1, compared with 0.14 lg mL-1 for Chloro-
quine. The results justify the use of this plant by natives of
West Africa in the treatment of malaria. Akuammidine and
w-akuammigine, are known to be potent l-opioid agonists,
although not particularly selective [57]. Kasim et al.
investigated the leaves of Struchium sparganophora (As-
teraceae), a plant used traditionally to treat malaria and
measles [58]. The isolated compounds (18–20) demon-
strated antimicrobial activities against the bacteria Staphy-
lococcus aureus (NCTC 6571), Klebsiella aerogenes
(Welcome Res. Lab.CN 345), Escherichia coli (NCTC
9001) and Proteus vulgaris (NCTC 8313), as well as against
the fungal strains Candida albicans (ATCC10231) and
Aspergilus niger (NCPF3149). Vernodalin (19) has been
also isolated from Vernonia amygdalina, along with ver-
nomygdin, and shown to demonstrate antitumour activities
[59]. The anti-malarial activity of ursolic acid (21), derived
from Spathodea campanulata (Bignoniaceae), popularly
known as African tulip tree, has been used to endorse the use
of the plant in southwestern Nigeria for malaria treatment by
drinking the decoction of its stem bark [44]. Ursolic acid
also has potential use as a cardioprotective compound [60]
and was found to be a weak aromatase inhibitor
(IC50 = 32 lM) [61]. Additionally, the antioxidant activi-
ties of compounds 22–27 isolated from the flowers, fruits,
leaf and stem bark of the same plant have been investigated
by Elusiyan et al. [62]. The results show that the antioxidant
principles isolated from the various parts of the plant are
verminoside (24), from the leaves, stem bark and flowers
(EC50 = 2.04 lg mL
-1), specioside (23), from the flowers
(EC50 = 17.44 lg mL
-1), kampeferol diglucoside (22),
from the leaves (EC50 = 8.87 lg mL
-1) and caffeic acid
(26), from the leaves and fruits. Verminoside has also been
isolated from Kigelia Africana, a plant used in Africa for
anti-inflammatory, anti-microbial, and anti-skin-aging
effects [63]. The anti-inflammatory activity of the com-
pound has been evaluated by cutaneous irritation in cell
cultures and reconstituted human epidermis and revealed
significant anti-inflammatory activity. The non antioxidant
components isolated in the study include ajugol (25), from
the stem bark and fruits and phytol (27), from the leaves
[62]. Alstonine is also known to exhibit antipsychotic and
anxiolytic properties [57].
3 Combretaceae, Compositae, Connaraceae,
Crassulaceae and Ebenaceae
A summary of the biological activities of the compounds
that mark the ethnobotanical uses of the plants of the above
families is given in Table 2. Guiera senegalensis (Com-
bretaceae) is often used in Nigeria for the treatment of
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malaria. The leaf extract of the plant harvested in Nigeria
showed positive anti-malarial activity in vitro in Plasmo-
dium yoelii nigeriensis [64]. The alkaloids harman (28) and
tetrahydroharman (29) and the methoxylated naphthalene
derivative guieranone A (30), Fig. 3, were shown to be the
active principles from this plant species harvested in Mali
and Sa˜o Tome´ [65, 66] in addition to its antifungal activity
[67]. The leaves of Tithonia diversifola (Compositae) have
also been extensively used in Nigerian traditional medicine
to treat malaria and fevers [45]. Oral decoction of the
leaves of Tithonia diversifolia are used for treatment of
hepatitis, diabetes, malaria, pain, chemoprevention and
anti-Helicobacter pylori [68–70], external application of
dried leaves on wounds and infusion of leaves for the
treatment of measles [70]. Goffin et al. [71] isolated the
sesquiterpene tagitinin C (31) from the leaves of this plant.
The anti-plasmodial compound 31 has been proven to be
the active principle responsible for the use of the plant
leaves in malaria treatment. Tagitinin C also demonstrated
therapeutic abilities against gastric ulcer [72]. Another
species from the Compositae family, Laggera pterodonta,
is often used against insect attack, athlete’s foot, skin
infections, pediatric malaria and wounds [73]. The plant is
also used in the treatment of hepatitis, arthritis, bronchitis
and nephritis. Five sesquiterpenes (32–35), exhibiting
antimicrobial activities, have been identified from the
species growing in China [74].
The leaf extract of Byrsocarpus coccineus (Connara-
ceae) has been used for the treatment of several venereal
diseases and as an antidote to arrow poisoning. It also acts
as a remedy for piles, while the decoction of the whole
plant is applied to swellings and tumours and to arrest
bleeding. The plant has also been reported as a remedy for
diarrhea. The isolated flavonoid and flavonoid glycosides
(37–39), have been respectively identified as quercetin
3-O-a-arabinoside, quercetin and quercetin 3-b-D-glucoside
[75].
Bryophyllum pinnatum (Crassulaceae) has diverse uses
in ATM. The flavonoid luteolin (18), epigallocatechin 3-O-
bFig. 2 Active principles from Allium sativum, Crinum glaucum,
Crinum jagus, Enantia chlorantha, Picralima nitida, Struchium
sparganophora, Spathodea campanulata, Guiera senegalensis and
Morinda lucida
Table 2 Summary of ethnobotanical uses versus measured biological activities of isolated secondary metabolites from; Combretaceae, Com-
positae, Connaraceae, Crassulaceae and Ebenaceae plant families










Treatment of malaria, diarrhea,







Iwalewa et al. [64], Ancolio
et al. [65], Combier et al.
[66], Silva and Gomez [67]
Compositae Tithonia
diversifola
Treatment of malaria, hepatitis,






Kuroda et al. [68], Castillo-
Jua´rez et al. [69], Adebayo





Against insect attack, athlete’s foot,
skin infections, pediatric malaria
and wounds. Also used in











Egharevba et al. [73]
Connaraceae Byrsocarpus
coccineus
Leaf decoction is used for the
treatment of venereal diseases and
as antidote to arrow poisoning and
as remedy for pile, while the
decoction of the whole plant is
applied to swelling and tumours
and also to arrest bleeding, the







Not tested Ahmadu et al. [75]
Crassulaceae Bryophyllum
pinnatum









Ogungbamila et al. [76]
Ebenaceae Diospyros
mespiliformis
Leaf decoction used for whooping
cough treatment and root extracts
as worm expellants
Root 42 Cytotoxicity Adeniyi et al. [83]
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syringate (40) and gallic acid (41) have been identified as
the active principles responsible for the antibacterial
activity of this plant, which explains why it is used in many
West African traditional medicinal recipes for the treat-
ment of ulcers [76]. The main antibacterial constituent was
found to be free gallic acid, which accounted for about
0.014 % w/w of the fresh aerial part. However, luteolin
and a new acylated flavan-3-ol, epigallocatechin-3-O-sy-
ringate, were isolated as minor constituents in the active
fraction. Luteolin exhibits a wide range of biological
activities, including antioxidant activity promotion of car-
bohydrate metabolism, and immune system modulation.
Other in vitro studies suggest luteolin has antiinflammatory
activity [77, 78], and that it acts as a monoamine trans-
porter activator [79], a phosphodiesterase inhibitor [80],
and an interleukin 6 inhibitor [77]. In vivo studies show
that luteolin affects xylazine/ketamine-induced anesthesia
in mice [80]. In vitro and in vivo experiments also suggest
the compound may inhibit the development of skin cancer
[81, 82]. Diosquinone (42), derived from the roots of
Diospyros mespiliformis (Ebenaceae), has shown very
good activity against all the cell lines tested with ED50
values ranging between 0.18 lg mL-1 against Human
Glioblastoma (U373) and 4.5 lg mL-1 against hormone
dependent human prostate cancer (LNCaP) [83]. The
relationship with the ethnobotanical use of this plant has
not however been established (the leaf decoction has been
used for the treatment of whooping cough and root extracts
used as worm expellants).
4 Euphorbiaceae
Amongst the plants of the Euphorbiaceae family, Tor-
Anyiin et al. [84] have reported the use of Alchornea
cordifolia in the treatment of malaria/fevers in Nigeria
(Table 3). Banzouzi et al. [85] identified ellagic acid (43),
Fig. 4, to be the active ingredient from the stem of this
plant, responsible for its anti-malarial activity. The leaves
of the same plant are used as a remedy for arthritis, muscle
pain and other inflammatory disorders. Okoye et al. carried
out an analysis of the volatile oil extracted from the fresh
leaves of A. cordifolia and revealed the presence of high
concentrations of eugenol (44: 41.7 %), cadinol (45:
2.46 %), caryophylene (56: 1.04 %), linalool (57: 30.59 %)
and (E)-a-bergamotene (59: 4.54 %). These compounds
could be contributing to the topical anti-inflammatory
effects of A. floribunda and A. cordifolia leaf extracts [86].
Okoye and Osadebe had also carried out a bioactivity-
guided fractionation of the ethyl acetate fraction of the
methanol leaf extract of the plant material, leading to the
isolation of a new flavonol glycoside, 3,5,7,30-tetrahydr-
oxyflavone-3-O-a-L-rhamnoside (61). The anti-inflamma-
tory activity (50 mg kg-1) of this compound was higher
than that of the standard anti-inflammatory drug, aspirin
(100 mg kg-1). The compound also significantly
(p \ 0.001) inhibited heat-induced haemolysis of human
erythrocytes in vitro [87]. These results demonstrated that
the anti-inflammatory activity of A. floribunda leaves may
be, in part, a result of the flavonol glycoside, compound 61.
Tagitinin C (31)
1β,9β−Dihydroxy-5,11(13)-dien-eudesman-
13-oic acid (32): R1 = H, R2 = OH
1β,3α-Dihydroxy-5,11(13)-dien-eudesman-
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Quercetin (38): R = H














































glucopyranoside (35): R1 = OGlc; R2 = H
9β-Hydroxy-pterodontic acid-9-O-β-D-





Fig. 3 Active principles from Tithonia diversifola, Laggera pterodonta, Byrsocarpus coccineus, Bryophyllum pinnatum and Diospyros
mespiliformis
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From this same family, Jatropha gossypifolia has been
used to treat various disease conditions such as cough,
tuberculosis, bacterial infections and cancerous growths
[88]. The phytochemical studies revealed the presence of
some secondary metabolites such as alkaloids, saponins
and tannins. There was no activity against the tested bac-
teria (Gram positive and Gram negative organisms at
2.5–100 mg mL-1). The seed extract however showed
significant antifungal activity. From the seeds of this plant
Falodun et al. carried out a spectroscopic analysis (1D and
2D NMR) of the colourless oil, giving 9-acetoxynerolidol
(76), which they suggested was the active ingredient [68]
Figs. 5–9.
5 Fabaceae, Ganodermataceae, Lamiaceae
and Loranthaceae
Our survey also involved five species from the Fabaceae or
Leguminoceae family, Table 4. These are Cajanus cajan
used in cancer treatment [89], Cassia alata used in the
treatment of skin diseases such as ringworm, eczema,
pruritis, itching, scabies, ulcers and other related diseases,
Berlina grandiflora used in the treatment of gastrointestinal
disorders, as well as Abrus precatorius and Cassia siamea,
both used in the treatment of malaria. A dichloromethane
(CH2Cl2) fraction of the leaves of Cajanus cajan had IC50
value 5–10 lg mL-1, with the two constituent stilbenes,
longistylins A (78) and C (79), being primarily responsible,
with IC50 values of 0.7–14.7 lM against the range of
cancer cell lines [89–91].
Ofodile et al. have isolated and characterized three
colossolactones; colossolactone E (80), colossolactone B
(81) and 23-hydroxycolossolactone E (82), from an n-
hexane:dichloromethane (2:7) extract of Ganoderma col-
ossum [92]. The antimicrobial screening of these com-
pounds revealed that colossolactone E and
23-hydroxycolossolactone E were active against Bacillus
subtilis and Pseudomonas syringae. Potency of the com-
pounds against the tested bacteria supports the use of this
mushroom in therapeutic medicine, since this genus of
mushrooms is known to possess anti-tumor, anti-cancer,
immunomodulatory and immunotherapeutic qualities [93].
Colossolactone B was not active against the bacteria. Other
colossolactones (V–VIII and G) and schisanlactone A have
also been isolated from the mushroom, Ganoderma
Table 3 Summary of ethnobotanical uses versus measured biological activities of isolated secondary metabolites from Euphorbiaceae plant
family










The leaves or leafy stems, as an infusion or chewed
fresh, are taken for their sedative, antimalarial
and antispasmodic activities to treat a variety of
respiratory problems including sore throat, cough
and bronchitis, genital–urinary problems including
venereal diseases and female sterility, and
intestinal problems including gastric ulcers,







Remedy for arthritis, muscle pain and other acute











Leaves are traditionally used as a remedy for











Treatment of various disease conditions such as
cough, tuberculosis, bacterial infections and
cancerous growths. The leaves of the plant are
traditionally being applied to boils, carbuncles,
eczema, itches, and veneral diseases and also used
as febrifuge, while its bark is used as
emmenagogue. Seeds are emetic, purgative and
used for cancer and body pain. The leaves and
seeds are considered as a purgative and are widely
used to treat obstinate constipation. Roots are used
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colossum, harvested from Vietnam, together with colos-
solactone E (80). The isolated compounds were evaluated
for inhibition of HIV-1 protease, with IC50 values for the
most potent compounds ranging from 5 to 13 lg/mL [94].
Colossolactone G showed the most promising anti-viral
activity, thus justifying the immunomodulatory and
immunotherapeutic qualities of this mushroom.
Hyptis suaveolens (Lamiaceae), used in the treatment of
respiratory tract infections, colds, pain, fever, cramps and
skin diseases has been investigated by Chukwujekwu et al.
[95]. A bioactivity-guided fractionation of the petroleum
ether extract of the leaves of this plant led to the isolation
of the abietane-type diterpenoid endoperoxide, 13a-epi-
dioxiabiet-8(14)-en-18-ol (83), a molecule with high anti-
plasmodial activity (IC50 = 0.1 lg mL
-1). This might
explain the usefulness of the plant for treating fever, which
might be due to malaria.
Among the other plants of the Leguminoceae family, the
antibacterial activity of 4-butylamine-10-methyl-6-hydroxy
cannabinoid dronabinol (84), isolated from Cassia alata,
could explain the use of this plant in the treatment of
ulcers, amongst other skin diseases [96]. The anthelmintic
activity of betulinic acid (85) was also used to validate the
use of Berlina grandiflora for treating gastrointestinal
disorders [97]. The investigations of Muhammad and
Amusa have reported the use of the stem bark of Abrus
precatorius (Leguminosae-Caesalpinioideae) in the treat-
ment of malaria [98]. Limmatvapirat et al. isolated abru-
quinone B (86), which showed anti-plasmodial activity,
with IC50 = 1.5 lg mL
-1 against the K1 strain of P. fal-
ciparum, from the stem bark of this plant [99]. Ajaiyeoba
et al. [100] also reported the use of the leaves and stem
bark of Cassia siamea in the treatment of malaria. Inves-
tigation of the leaves of this plant led to the isolation of
emodin (87), lupeol (88) and cassiarin A (89), with IC50
values of 5.0 lg mL-1 against the K1 strain for both
compounds 87 and 88 and an IC50 value of 0.02 lM for



















































Fig. 4 Active principles from Alchornea cordifolia—I
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medicine, the stem bark of Cassia siamea is used as a mild,
pleasant, safe purgative; a decoction of the bark is given to
treat diabetes; a paste is used as a dressing for ringworm
and chilblains; the roots are used as an antipyretic; and the
leaves are used for the treatment of constipation, hyper-
tension, and insomnia [101]. The vasodilator effect of
cassiarin A, could explain the use of this plant in the
treatment of hypertension, amongst other ailments [102].
From the leafy twigs of Loranthus micranthus (Lo-
ranthaceae), a parasitic growing on Hevea brasiliensis,
compounds 90–95 have been isolated [103]. The antioxi-
dant activities of the isolated compounds were evaluated
using the 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay,
giving IC50 values varying from 23.8 and 50.1 lM, all
being more active than the reference drug chlorogenic acid
(with IC50 = 67.9 lM) [103]. The immunostimulatory
activities of 2,3-dimethoxy-benzo[a,b]cyclopentenyl-
30,30,50-trimethyl pyran-4-carboxylic acid (96) and lupinine
(97) have been used to validate the use of the leaves of this
same plant in the treatment of several diseases including
immune-modulating diseases [104].
6 Malvaceae, Meliaceae, Rubiaceae, Rutaceae
and Simaroubaceae
Sida acuta (Malvaceae) is widely used for the treatment of
malaria in West Africa, among other diseases [105]. The
ethanol, aqueous and chloroform extracts are known to
display antiplasmodial activity at 3.90, 0.92 and
0.87 lg mL-1 respectively against the P. falciparum


















































Fig. 5 Active principles from Alchornea floribunda—II
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cryptolepine (98) as the active ingredient from samples
collected in Ivory Coast, West Africa. Cryptolepine ana-
logues have also been isolated from Cryptolepis sangui-
nolenta (Periplocaceae), harvested from diverse locations










Longistylin A (78): R1 =  Prenyl,
                             R2 = OMe
Longistylin C (79): R1 = OMe,


























































bFig. 6 Active principles from Jatropha gossypifolia, Cajanus cajan,
Ganoderma colossum, Hyptis suaveolens, Cassia alata, Berlina
grandiflora, Abrus precatorius and Cassia siamea





































































Fig. 7 Active principles from Loranthus micranthus, Sida acuta and
Ixora coccinea
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Different parts of Azadiracta indica and Khaya gran-
difoliola (Meliaceae) are also used in West Africa for tra-
ditional preparations to treat malaria [115–117]. The
limonoid gedunin (99), isolated from the leaves of A.
indica, inhibits P. falciparum at IC50 of 1.25 lg mL
-1
[115, 118]. Gedunin was also isolated from K. grandifoli-
ola, along with the other limonoids 2,6-dihydroxyfissino-
lide (100), methylangolensate (101), 7-deacetylkhivorin
(102), 1-deacetylkhivorin (103) and 6-acetylswietenolide
(104), exhibiting significant antiplasmodial activities [118].
Additionally, gedunin has displayed anticancer activities
[119] and Hsp90 inhibition [120].
Among the surveyed plants of the Rubiaceae family,
Pavetta crassipes has been used in handling respiratory
infections and abdominal disorders [121], while the leaves
and stems of Morinda lucida are used in treating malaria
[45, 84] and Ixora coccinea is used to treat a variety of
infections, including hypertension, menstrual irregularities,
sprains, chronic ulcers and skin diseases [122]. A bioactive
flavonoid (quercetin-3-O-rutinoside, 105) has been isolated
from the aqueous extract of P. crassipes leaves, which
showed activity against some pathogenic microorganisms,
including Streptococcus pyogenes, Corynebacterium ulc-
erans, Klebsiella pneumoniae, Neisseria gonorrhoeae,
Pseudomonas aeruginosa, and Escherichia coli at a con-
centration \ 50 mg mL-1 [121]. The compound had
minimum inhibitory concentration (MIC) ranging from
6.25 to 12.5 mg mL-1 and minimum bactericidal concen-
tration (MBC) ranging from 12.5 to 25 mg mL-1. This
supports the ethnomedicinal use of the plant in the treat-
ment of respiratory infections and abdominal disorders
[121].
The ethanol, CH2Cl2 and petroleum ether extracts of
the leaves and stems of Morinda lucida exhibited
respective IC50 values of 5.70, 5.20 and 3.90 lg mL
-1
[123]. Cimanga et al. [124] identified ursolic acid (21) as
the active ingredient, which exhibited antiplasmodial
activity at IC50 of 3.10 lg mL
-1 against the chloroquine-
sensitive strain of P. falciparum. Idowu et al. [122]
identified a doubly linked, A-type proanthocyanidin tri-
mer and other constituents of Ixora coccinea leaves. The
antioxidant and antibacterial properties of the identified
compounds (93, 106–111) were also investigated. All
tested compounds inhibited the growth of B. subtilis,
while only epicatechin (93) and quercetin-3-O-a-L-
rhamnopyranoside (110) inhibited the growth of E. coli.
Antioxidant evaluation of isolated compounds revealed
that ixoratannin A-2 (107) and cinnamtannin B-1 (108)
were the most active compounds in DPPH, inhibition of
lipid peroxidation and nitric oxide radical scavenging
assays. This could explain why the plant is effective in the
treatment of chronic ulcers. The presence and antiplas-
modial property of the alkaloid fagaronine (112), with an
IC50 of 0.018 lM against the 3D7 strain of P. falciparum,
in Fagara zanthoxyloides (Rutaceae), could explain why
the roots of this plant are used in preparations against
malaria, amongst other applications in ATM [125].
The leaves and stems of plants from the Quassia species
(Simaroubaceae) are generally employed in anti-malarial
preparations, Q. amara (also called bitterwood tree) having
the highest anti-malarial reputation for curative and pre-
ventive purposes in the Simaroubaceae family [45, 126].
Simalikalactone D (113), samaderine X (114), samaderine
Z (115), samaderine B (116) and samaderine E (117) have
been isolated from Q. amara and Q. indica, displaying anti-
plasmodial properties in the range 0.010 and




































7-Deacetylkhivorin (102): R1 = OH, R2 = CO2Me



















Fig. 8 Active principles from Azadiracta indica, Khaya grandifoli-
ola and Pavetta crassipes
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also isolated from French Guianian Quassia amara. The
compound displayed anti-malarial activity and was shown
to be less toxic than simalikalactone D (113) [129].
Odukoya et al. [130] have shown that the alcohol and
petrol extracts of seeds of Aframomum danielli
(Zingiberaceae), used traditionally as a food spice and also
as an anti-inflammatory agent, inhibit the soya 5-lipoxy-
genase enzyme and thus may show anti-inflammatory
activity. Compounds isolated from the active extract were


































































































































































Fig. 9 Active principles from Ixora coccinea, Fagara zanthoxyloides, Quassia amara, Quassia indica and Aframomum danielli
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derivatives. Phytyl plastoquinone (119) and heptaplasto-
quinone (120) were respectively isolated from the petrol
and alcohol extracts, both compounds inhibiting 5-lipoxy-
genase at 6.25 and 18.5 lM, respectively, compared with
the standard drug Fisetin, which inhibited the enzyme at
0.92 lM, Table 5.
7 Conclusions
The results presented in this review represent an overview
of the biological activities of selected NPs isolated from
plants used in traditional medicine in Nigeria. Our inten-
tion has been to focus on those plants whose ethnobotanical
uses correlate with the biological activities of the derived
NPs. Even though this report does not claim to be
exhaustive, the goal of documenting the baseline
knowledge, from which further investigations could be
carried out, has been achieved. This work has also led to
the collection of a chemical database for plants used in
traditional medicine in Nigeria (Naijaplant), to be made
available separately. The plant sources, geographical col-
lection sites, chemical structures of pure compounds as
well as their spectroscopic data, were retrieved from lit-
erature sources comprising data collected from 176 articles
from 68 peer reviewed journals, spanning the period 1971
to 2013. Our survey consisted in collecting data from the
literature sources, mainly from MSc and PhD theses from
Nigerian University libraries and also using the author
queries in major natural product and medicinal chemistry
journals. The collected data includes plant sources, uses of
plant material in traditional medicine, plant families,
region of collection of plant material, isolated metabolites
and type (e.g. flavonoid, terpenoid, etc.), measured
Table 4 Summary of ethnobotanical uses versus measured biological activities of isolated secondary metabolites from; Fabaceae, Ganoder-
mataceae, Lamiaceae and Loranthaceae plant families









Cancer treatment, for the treatment
diabetes and as an energy
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Paterson [93], El
Din et al. [94]
Lamiaceae Hyptis
suaveolens
Treatment of respiratory tract
infections, colds, pain, fever,





Leguminosae Cassia alata Treatment of skin diseases such as
ringworm, eczema, pruritis,
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precatorius










Treatment of malaria. In Asia, stem
bark is used as a mild, pleasant,
safe purgative; to treat diabetes; a
paste is used as a dressing for
ringworm and chilblains; the roots
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biological activities of isolated compounds, and any com-
ments on significance of isolated metabolites on the che-
motaxonomic classification of the plant species (as
commented in the literature). This survey suggests that
information gathered from compounds derived from Afri-
can medicinal plants, in particular from Nigeria, could be a
suitable starting point for extensive drug discovery pro-
jects, especially for some of the most frequently mentioned
diseases like malaria, since malaria is the most endemic
disease in Africa and plants used in the treatment of
malaria have been the most investigated on the continent
[39, 40, 45, 131–134].
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
Table 5 Summary of ethnobotanical uses versus measured biological activities of isolated secondary metabolites from; Malvaceae, Meliaceae,
Rubiaceae, Rutaceae and Simaroubaceae plant families
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Treatment of malaria, as remedy
against rheumatoid arthritis.
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[123], Cimanga et al.
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Ixora coccinea Treatment of a variety of infections;
hypertension, menstrual
irregularities, sprains, chronic





Idowu et al. [122]
Rutaceae Fagara
zanthoxyloides
Treatment of malaria. The stem and
the root of the plant are both used as
chewing stick in Nigeria
particularly among the Yoruba
ethnic group in the South-Western





Simaroubaceae Quassia amara Treatment of malaria, as a digestive,
treat fever, against hair parasites
(lice, fleas), and Mosquito larvae in
ponds (and do not harm the fishes).
Extracts of Quassia wood or bark
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Used as traditional food spice, as an
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